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scarring.
Fig 2. Sterile matrix graft in situ following excision of
scarred bed.
Abbreviation used:
VPA: valproic acidINTRODUCTION
Valproic acid (VPA), a widely used antiepileptic
drug and mood stabilizer, has myriad cutaneous side
effects including transient alopecia, exanthems, and
vasculitides.1-3 We report on a patient who, in the
setting of VPA use, presented with nail nonadher-
ence secondary to sterile matrix scarring and pro-
pose nail bed excisionwith sterile matrix grafting as a
surgical solution.
CASE REPORT
A 26-year-old epileptic woman who has taken
VPA 500 mg twice a day since childhood, presented
with a 1-year history of onycholysis and a dorsal
pterygium of her right third digit (Fig 1). Preoperative
fungal cultures were negative, and magnetic reso-
nance imaging was significant for increased thick-
ness of the nail matrix. The patient opted for
reconstruction of the nail matrix using a split toenail
matrix graft.
The right third digit nail plate was lifted and
removed. Dense scarring with distortion of the sterile
matrix was noted. This was excised with care not to
disturb the germinal matrix, yielding a 10-mm 3
5-mm defect. The left great toenail plate was lifted
and a sterile matrix graft 10 3 5 mm was obtained
transferred, and secured to the sterile matrix of the
right middle finger (Fig 2). Using 6-0 and 7-0 Ethicon
plain gut suture, simple interrupted sutures were
placed at the 4 corners of the graft. Sutures were
subsequently placed in between the existing ones to
prevent avulsion. The nail plate was replaced in the
eponychial fold to maintain patency, and dressings
were applied. Both five-month and long-term
postoperative follow-up found a well-healing
surgical site with nail plate adherence and minimal
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Fig 3. Postoperative follow-up demonstrating nail plate adherence without residual
leukonychia both at 5 months and long-term (17 months) (A and B) with minimal great toe
donor site morbidity (C and D).
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Patients with nail deformities seek treatment of
both cosmetic and functional deformities. The nail
not only contributes to the overall aesthetics of the
hand but is also involved in function, including fine
pinch, pulp stability, and dorsal protection.
Anticonvulsant medications, including VPA, have
been linked to various nail deformities including
hyperpigmentation and onychodystrophy.4-6 One
such deformity, onycholysis, or separation of the
nail plate from the nail bed, in association with
VPA use has been described in several case
reports.7,8 The authors speculate that onycholysis
formed secondary to a disturbance of zinc
metabolism caused by a combination of sodium
valproateeinduced malabsorption and systemicchelation of zinc.9,10 A second such deformity is
onychomadesis, or separation of the nail plate from
the proximal nail fold with shedding of the nail plate.
A study by Poretti et al11 describes onychomadesis
4 years after initiation of VPA. Lastly, changes in nail
pigment have been found in association with VPA
therapy.12
Although the aforementioned nail deformities
have been said to resolve after discontinuation
of VPA, treatment of these deformities is challenging
when the cessation of VPA is not medically advisable.
Previous attempts to replace the nail matrices with
skin or dermal grafts have been unsuccessful.13 A
large body of literature supports good functional and
cosmetic outcomes of free nail matrix grafts in the
treatment of nail avulsion injuries.14 The use of a
Fig 4. A comparison of the patient’s preoperative presentation (A) and postoperative
results (B).
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to help the nail regain the smooth and adherent
qualities of a normal-appearing nail.15
Our patient presented with a thickened and
scarred sterile matrix, which resulted in formation
of a dorsal pterygium and onycholysis, findings that
have been substantiated in the literature.13 Our
surgical approach stemmed from the principle that
a normal sterile matrix is required for nail adherence
and growth. Therefore, we first excised the area of
scarred sterile matrix and subsequently harvested a
sterile matrix graft from the great toe for use in
reconstruction of our defect. This surgical approach
follows the central plastic surgery tenant of replacing
like tissue with like tissue while inflicting little donor
site morbidity.CONCLUSION
Onycholysis, onychomadesis, and nail hyperpig-
mentation are described as rare side effects of VPA
therapy. Several case reports suggest resolution of
the deformities with cessation of VPA therapy.
However, there are some patients who require
continued antiepileptic therapy. In such patients,
we suggest sterile matrix grafting as a surgical
intervention to correct this rare adverse effect.
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